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1 |  INTRODUCTION
Multiple myeloma (MM) can cause cerebral venous sinus 
thrombosis (CVST) or cranial neuropathies. Combined uni-
lateral palsies of cranial nerves IX- XII are called Collet- 
Sicard syndrome (CSS), which can be caused by MM 
extramedullary plasmacytomas (MM- EP) or CVST. Our case 
report illustrates a unique combination of MM- EP and CVST 
causing CSS.
Multiple myeloma (MM) is a malignant clonal plasma cell 
dyscrasia typically presenting with anemia, hypercalcemia, 
bony skeletal symptoms, and/or renal failure and comprises 10% 
of hematological malignancies.1 Neurological involvement in 
MM can occur due to the following2: (i) direct infiltration (eg, 
inflammatory neuropathy); (ii) remote effects of the disease 
[eg, hypercoagulability causing cerebral venous sinus thrombo-
sis (CVST)]3; or (iii) complications from treatment (eg, seizures 
from melphalan). Central nervous system (CNS) involvement 
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Abstract
In a patient with Collet- Sicard syndrome and multiple myeloma, both extramedullary 
plasmacytomas and internal jugular vein- sigmoid sinus thrombosis should be consid-
ered as they can coexist.
K E Y W O R D S
cranial neuropathy, multiple myeloma, plasmacytoma
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is rare (approximately 1% of MM cases)4 and usually due to 
extramedullary plasmacytomas (EP) from longer- standing ad-
vanced stage MM (MM- EP). EP comprise 1% of head and neck 
tumors5 and have a predilection for the skull base6; intracranial 
MM- EP can therefore manifest as cranial neuropathies depend-
ing on the site of the lesion.7 MM- EP carry a poor prognosis, 
with median overall survival of approximately 2 months.8
Collet- Sicard syndrome (CSS) is a rare presentation of 
combined unilateral palsies of cranial nerves IX, X, XI and 
XII from skull base lesions that affect both the jugular foramen 
pars nervosa and the hypoglossal canal. In a recent review of 51 
CSS cases reported in the literature, 40% are caused by malig-
nancies, including EP, and 33% by vascular disease including 
CVST.9 However, the majority of the reported EP cases causing 
jugular foramen syndromes such as CSS are solitary plasmacy-
tomas rather than MM- EP.10 There are no reported CSS cases 
caused simultaneously by both MM- EP and CVST.
2 |  CASE EXAMINATION
2.1 | Case history
A 57- year- old female initially presented at an external facility 
with fatigue and anemia. She was found to have a monoclonal 
band on serum protein electrophoresis and 62% plasmocytosis 
on bone marrow biopsy which confirmed the diagnosis of MM. 
She was treated with dexamethasone 40mg weekly and a 21- day 
cycle of lenalidomide 25 mg once a day for 6 months. Repeat 
bone marrow examination revealed no excess plasma cells, 
and the lenalidomide dose was reduced to 10mg. However, she 
elected to transfer to our facility a year later after complaining 
of four months of hoarseness of voice, difficulty in swallowing, 
and night sweats despite her ongoing treatment.
Initial blood tests revealed normal renal function and cal-
cium level, and the following abnormal results: a normocytic 
normochromic anemia with a hemoglobin of 7.7 g/dl [nor-
mal range (NR) 11.5– 16.5 g/dl], monoclonal band on serum 
protein electrophoresis (0.15 g/dl; NR 0), and beta- 2 micro-
globulin raised at 7152  ng/ml (NR 670– 2143). Serum free 
light chain (FLC) assay revealed elevated kappa (κ) light 
chains (4840 mg/L; NR 6.7– 22.4) with normal lambda (λ) 
light chains (12.9 mg/L; NR 8.3– 27.0) giving an elevated κ/λ 
ratio of 375.2 (NR 0.26– 1.65). There were no bone lesions 
on cross- sectional magnetic resonance imaging (MRI), and 
a computed tomography (CT) scan of the head was reported 
as normal.
2.2 | Differential diagnosis
The investigations were in keeping with suboptimal MM dis-
ease control. Her therapy was optimized to the VRD regimen: 
weekly subcutaneous bortezomib (V) 2.5mg (calculated as 
1.3 mg/m2 body surface area) once a week for three weeks 
followed by one- week break, lenalidomide (R) 25 mg once a 
day for three weeks followed by one- week break, and dexa-
methasone (D) 40 mg once a week. However, her dyspho-
nia, dysarthria, and dysphagia progressed, and she developed 
generalized body fatigue, weakness and episodes of tetany, 
which led to an urgent admission a month later.
2.3 | Investigations
Repeat blood tests revealed worsening anemia with a hemo-
globin of 5.0  g/dl, thrombocytopenia (platelet count of 
128  ×  109/L; NR 150– 400), hypokalemia (2.50mmol/L; 
NR 3.3– 5.4), hyponatremia (131  mmol/L; NR 136– 145), 
hypomagnesaemia (0.44  mmol/L; NR 0.66– 1.07), hypoc-
alcaemia (1.9mmol/L corrected; NR 2.15– 2.55), and hypo- 
albuminemia (30.6 g/L; NR 35– 55), but normal renal function 
and insignificantly elevated liver function tests. These results 
led to the diagnosis of Fanconi syndrome (FS) being caused 
by light chain proximal tubulopathy (LCPT). We corrected 
the electrolyte imbalances with the help of the nephrology 
team, but her neurological symptoms persisted so she was 
reviewed by the neurology team.
Cranial nerve examination revealed absent gag reflex, left 
palatal weakness with contralateral uvula deviation, weak-
ness of the left sternocleidomastoid and trapezius muscles, 
and a weak, wasted and fasciculating tongue that was devi-
ated to the left. Gustatory function in the posterior third of 
the tongue was difficult to assess, and the rest of the neuro-
logical examination was normal. The signs found were all 
in keeping with combined multiple ipsilateral lower cranial 
neuropathies consistent with CSS.
MRI brain scan with contrast revealed reduced T1 signal 
in the marrow of the left clivus, petrous and mastoid temporal 
bones, with gadolinium enhancement extending to the jugu-
lar foramina and hypoglossal canals bilaterally, worse on the 
left. The findings were in keeping with intracranial MM- EP. 
Dedicated imaging of the vasculature with CT venography 
further confirmed CVST in the left sigmoid- jugular sinus 
complex extending to the proximal internal jugular vein 
(Figures 1- 5).
2.4 | Treatment
The VRD therapy was intensified for the MM- EP and 
continued with good effect such that at 6  weeks κ was 
311.0 ml/L, λ was 8.57 mg/L, and κ/λ ratio was much im-
proved at 36.3. The patient was also commenced on rivaroxa-
ban (15 mg twice daily for three weeks followed by 20 mg 
once a day) for the CVST, as she did not want injections of 
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low- molecular- weight heparin (LMWH), and there was no 
reliable warfarin service near her. She was followed up by 
the hematology service regularly in our hospital's chemother-
apy unit to ensure adherence to the VRD treatment.
2.5 | Outcome and follow- up
At 3 months, she had complete resolution of her cranial nerve 
symptoms with no further complications and had found it 
easy to comply with both rivaroxaban and the VRD regimen. 
Repeat neuroimaging at this stage showed partial resolution 
of the CVST; the MM- EP had marginally increased from 
F I G U R E  1  T2- weighted thin- slice fast imaging employing 
steady- state acquisition (FIESTA) magnetic resonance imaging (MRI) 
sequence shows left clival and petrous bone T2 hypointense mass 
(open arrows) displacing the left internal carotid artery anteromedially 
(diamond arrow), with left mastoid effusion (asterisk)
F I G U R E  2  T2- weighted thin- slice FIESTA MRI sequence shows 
thickened left glossopharyngeal and vagus nerves (open arrows) 
entering a narrowed jugular foramen pars nervosa
F I G U R E  3  T2- weighted thin- slice FIESTA MRI sequence shows 
a thickened left hypoglossal nerve (open arrow) within hypoglossal 
canal narrowed by inferior aspect of mass
F I G U R E  4  T1- weighted MRI with contrast showing left clival, 
prevertebral, and petrous mass obscuring left jugular bulb (open arrow)
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2.7 cubic centimeters (cc) to 3.1 cc (approximately 14% in-
crease), which qualified as stable disease as per the response 
evaluation criteria in solid tumors (RECIST) criteria.11 We 
therefore decided to continue the VRD regimen and antico-
agulation for a total of 6 months, in line with respective inter-
national guidelines.12
3 |  DISCUSSION
Our patient did not have the appropriate treatment for MM 
at the outset, which may have led to early extramedullary 
disease progression. Disease dissemination usually occurs 
years later even in stable patients treated with autologous 
stem cell transplant.3 By the time she presented to our facil-
ity, she required salvage therapy and as per guidelines we 
instituted the VRD regimen,13 a regimen similar to other 
regimens such as the carfilzomib- based KRD (carfilzomib, 
lenalidomide and dexamethasone),14 which have been shown 
to improve prognosis specifically in disseminated MM in-
cluding MM- EP.15 There is some evidence that in relapsed 
or refractory MM patients with MM- EP, a more intensive 
“lymphoma- like” polychemotherapy regimen can be used.16 
Radiotherapy can offer further prolongation of disease- free 
survival,17 but our patient's MM- EP was deemed stable as per 
the RECIST criteria.11 Indeed, there are reports of significant 
reduction in intracranial MM- EP and improved prognosis 
with salvage regimens without the need for radiotherapy.14 
Surgical treatment is not well established for skull base plas-
macytomas, although some recommend salvage surgery in 
cases of recurrent/persistent disease,10,18 which was not per-
tinent to our case.
Our patient's MM- EP presented with CSS. CSS can be the 
first presenting feature of MM,10,19 or a presenting feature of 
dissemination of previously controlled MM3; mortality can 
be within months of such presentations.20  Jugular foramen 
syndromes and CSS are not the only cranial neuropathies 
that herald MM. Depending on the site of infiltration at the 
skull base,7  MM can first present with: (i) isolated palsies 
of, for example, the oculomotor,21 abducens,22 or hypoglos-
sal23 nerves; or as (ii) multiple cranial neuropathies that are 
either adjacent (eg, of the trigeminal and abducens nerve)24 
or separate (eg, optic neuropathy in combination with other 
cranial neuropathies).25 Even if the presenting feature is cra-
nial, it remains important to look for concurrent neurological 
involvement in the spinal cord26 or peripheral nerves,27 which 
we did in our patient on clinical examination.
The association between MM and FS is well known from 
the 1950s,28 and in adults FS usually occurs due to intracyto-
plasmic deposition of monoclonal (usually κ) light chains in 
the proximal tubular epithelial cells, and this leads to LCPT.29
Patients with multiple myeloma are at an increased risk of 
venous thromboembolism, and thromboprophylaxis is recom-
mended, with either aspirin or LMWH depending on disease, 
patient, and treatment- related factors.30 For our patient, the 
initiation of appropriate chemotherapy occurred only shortly 
before the second admission caused by FS, and thrombopro-
phylaxis had therefore not been commenced. It is unlikely 
our patient developed CVST at this second admission as she 
did not have headache or visual disturbance, which suggests a 
more subacute onset of the thrombosis. While the MRI brain 
scan picked up the MM- EP in our case, the diagnosis of CVST 
was only clarified after definitive CT venography. Indeed, ded-
icated skull- based CT imaging with additional techniques such 
as multidetector- row CT have been shown to adequately diag-
nose the extent of infiltration and even the cause of CSS.31,32 
CVST can occur with intracranial MM- EP,3 but only <5% of 
CVST cases present with multiple cranial nerve palsies,33 and 
CSS caused by CVST has only been described in five cas-
es2,33- 36 based on our literature review (see Table 1).
Warfarin or LMWH is the recommended treatment for 
thrombotic events in MM,30 and warfarin is the internation-
ally accepted standard treatment of CVST.37 However, the risk 
of bleeding needs to be balanced against the risk of recurrent 
thrombosis on an individual basis, especially in hematological 
malignancies where thrombocytopenia increases bleeding risk, 
especially in the first 6 months of anticoagulation.30 Our patient 
did not have thrombocytopenia at the time of commencing anti-
coagulation, and as a team we agreed the risk of further CVST 
or other thromboses was higher in the context of her MM disease 
F I G U R E  5  Computed tomography (CT) venography of the 
intracranial vasculature showing no flow in left sigmoid- jugular 
complex (open arrow) in keeping with occlusive cerebral venous sinus 
thrombosis
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being so active, and it is recommended that in such cases an-
ticoagulation should be continued until the underlying disease 
is controlled.30  Warfarin was difficult to institute because of 
poor local setups for adequate monitoring and dosing, and our 
patient also did not want injections of LMWH. Direct oral anti-
coagulants (DOACs) such as rivaroxaban and dabigatran are not 
recommended because of lack of evidence. For CVST, there is 
some evidence to show safe and efficacious treatment with rivar-
oxaban.38,39 Only several months after this case have we noted 
the recently published randomized controlled trial evidence that 
shows dabigatran is noninferior to warfarin in treating CVST.40
Our case benefited from being managed at a tertiary re-
ferral center, which had the best diagnostic and therapeutic 
options available in the region, except for stem cell therapy 
for which the closest center would have been in South Africa. 
Our report is limited by the paucity of initial evaluation, in-
cluding laboratory workup, from the external facility where 
she first presented in 2018.
4 |  CONCLUSION
MM can affect the nervous system and can manifest in many 
ways including multiple cranial neuropathies such as CSS, 
which can even be the first presenting signs of the disease. 
Patients with MM are more prone to prothrombotic events 
such as CVST, which can be prevented by timely throm-
boprophylaxis. Recent advances in MM treatment have 
improved survival, but MM as a systemic disease can com-
plicate to FS or progress to MM- EP. Urgent salvage regimens 
such as VRD can be used to treat relapses and/or progression, 
resulting in improvement without the need to for surgery or 
radiotherapy as our case illustrates.
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